讨论
liukc0072015-05-07 22:27
简介:Synageva Biopharma Corp.是一个临床阶段的生物制药公司,于1993成立。该公司主要致力于研发,发展和使治疗产品商品化,以解决危及患者生命的罕见疾病和未满足的医疗需求。Synageva公司拥有多种蛋白质管道疗法,包括用于溶酶体贮积症的两种酶取代疗法和用于其他阶段还没有认可的治疗办法的严重遗传疾病的额外程序。该公司引导的程序,sebelipase α,是一种现阶段在北美洲和欧盟所进行的临床研究下,重组人体溶酶体酸性脂肪酶的项目,其产品用于病人早发和晚发的LAL Deficiency疾病,这是一种罕见的,毁灭性的疾病,会造成重大的发病率和死亡率。Synageva目前在全球的临床试验中评估 sebelipaseα项目,并且sebelipaseα项目已经被美国食品和药物管理局,欧洲药品局,日本健康部,劳动福利部授予了孤儿药地位。此外,Sebelipaseα项目已经获得了FDA的快速审核资格。Synageva公司尚未获得售卖该产品的批准,并且目前也没有销售任何产品。
今开: | 昨收:238.6 |
最高: | 最低: |
涨停价: | 跌停价: |
总市值:8867100389.6 |
liukc0072015-05-07 22:27
Chris32015-05-07 10:04
We talked about this...we talked abt this...hope you have followed. $SYNAGEVA BIOPHARMA CORP(GEVA)$查看全文
淡投2015-05-07 05:47
$Pharmacyclics(PCYC)$ and $SYNAGEVA BIOPHARMA CORP(GEVA)$ largest and 3rd largest holding of Baker Bros. $因塞特医疗(INCY)$ and $Seattle Genetics(SGEN)$, 2nd and 4th largest!查看全文
淡投2015-05-07 01:54
$SYNAGEVA BIOPHARMA CORP(GEVA)$ Baker Brothers查看全文
liukc0072015-05-06 23:42
疑夕2015-05-06 21:55
$SYNAGEVA BIOPHARMA CORP(GEVA)$ 这笔孤儿药收购溢价真多查看全文
割资本主义羊毛2015-05-06 20:49
$SYNAGEVA BIOPHARMA CORP(GEVA)$ baker这31%的持股又翻倍了,你们兄弟俩真是看着每月翻一只的节奏啊。查看全文
青春旧照片2015-05-06 20:36
$58同城(WUBA)$ 58的收购 跟 $SYNAGEVA BIOPHARMA CORP(GEVA)$ $BORDERFREE(BRDR)$ 比起来差远了查看全文
石槌柔佛2015-05-06 20:31
$SYNAGEVA BIOPHARMA CORP(GEVA)$
nasdaq在4月15日还有 4.3m股的空仓,期待逼空吧!
4/15/2015 4,359,793查看全文
玲志姐姐2015-05-06 20:08
$SYNAGEVA BIOPHARMA CORP(GEVA)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2016-02-16 AccNo: 0000858744-16-000037 Size: 8 KB 网页链接
$SYNAGEVA BIOPHARMA CORP(GEVA)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2015-06-24 AccNo: 0001144204-15-038778 Size: 116 KB 网页链接
$SYNAGEVA BIOPHARMA CORP(GEVA)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2015-06-23 AccNo: 0001193125-15-231331 Size: 32 KB 网页链接
$SYNAGEVA BIOPHARMA CORP(GEVA)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2015-06-23 AccNo: 0001193125-15-231328 Size: 32 KB 网页链接
$SYNAGEVA BIOPHARMA CORP(GEVA)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2015-06-24 AccNo: 0001144204-15-038778 Size: 116 KB 网页链接
$SYNAGEVA BIOPHARMA CORP(GEVA)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2015-06-23 AccNo: 0001193125-15-231331 Size: 32 KB 网页链接
$SYNAGEVA BIOPHARMA CORP(GEVA)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2015-06-23 AccNo: 0001193125-15-231328 Size: 32 KB 网页链接
$SYNAGEVA BIOPHARMA CORP(GEVA)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2015-06-23 AccNo: 0001193125-15-231324 Size: 32 KB 网页链接
$SYNAGEVA BIOPHARMA CORP(GEVA)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2015-06-23 AccNo: 0001193125-15-231317 Size: 32 KB 网页链接
$SYNAGEVA BIOPHARMA CORP(GEVA)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2015-06-23 AccNo: 0001193125-15-231310 Size: 32 KB 网页链接